Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

NCT07813767 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT07813767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07813767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2026
Completion date
December 31, 2028
Enrollment
398 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis